Skip to main content
Smart Investors Daily
MC

NASDAQ · MCRB

Seres Therapeutics, Inc.

Healthcare · Biotechnology

$1.33

Down-$0.09 (-6.77%)

Updated Nov 21, 2026, 1:41 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
151.06M
P/E ratio
27.95
Dividend yield
0.00%
52-week range
$1.30 – $18.86
Volume
54.69K
Avg. volume
192.86K

Price performance · MCRB

MCRB price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

MCRB closed at $1.33 after 20 trading sessions, down 36.36% for the selected period.

Last close
$1.33
Period change
-36.36%
Period low
$1.33
Period high
$2.09
Daily close
View OHLC price history
MCRB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$1.47$1.47$1.31$1.3354.69K
Nov 18, 2026$1.43$1.58$1.413$1.4442.97K
Nov 17, 2026$1.39$1.50$1.33$1.4155.58K
Nov 16, 2026$1.38$1.70$1.38$1.41186.62K
Nov 13, 2026$1.38$1.48$1.3246$1.4059.95K
Nov 12, 2026$1.48$1.48$1.30$1.4174.19K
Nov 11, 2026$1.54$1.585$1.35$1.50240.39K
Nov 10, 2026$1.68$1.74$1.55$1.5639.48K
Nov 9, 2026$1.94$2.05$1.68$1.70184.23K
Nov 6, 2026$2.13$2.26$1.96$1.9882.28K
Nov 5, 2026$2.15$2.20$2.005$2.0994.59K
Nov 4, 2026$1.9941$2.14$1.76$2.0994.99K
Nov 3, 2026$1.97$1.98$1.85$1.9653.11K
Nov 2, 2026$1.84$2.00$1.81$1.8344.16K
Oct 30, 2026$1.92$1.92$1.75$1.77120.11K
Oct 29, 2026$1.90$2.0293$1.81$1.9578.51K
Oct 28, 2026$1.77$1.93$1.675$1.7987.5K
Oct 27, 2026$2.00$2.00$1.70$1.80165.35K
Oct 26, 2026$2.11$2.185$1.98$1.9853.07K
Oct 23, 2026$2.13$2.17$2.00$2.0969.71K

Latest MCRB news

The latest Smart Investors Daily articles mentioning MCRB.

MCRB research

Overview

Company profile and research snapshot.

Company profile

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.25
Implied upside
—
Analysts
—
MCRB recent ratings
DateFirmRatingTarget
Jun 23, 2026HC Wainwright & Co.Buy—
Mar 13, 2026Canaccord GenuityBuy—
Sep 24, 2025Canaccord GenuityBuy—
May 8, 2025Chardan CapitalNeutral—
Mar 20, 2025Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)

Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to submit plans for the next irEC study design to the FDA in Q1 2027 Study builds on encouraging investigator-sponsored trial (IST) results, in which 12 of 15 participants (80%) with moderate-to-severe irEC achieved an immunosuppressive-free clinical response of diarrhea following tre

Yahoo · Nov 3, 2026

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study support the SER-155 mechanisms of strengthening the mucosal epithelial barrier and reducing systemic inflammation CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Pha

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.